Westport, CT, March 22, 2022 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company commercializing an innovative signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that it entered in a definitive […]
Other News
Genomics Testing Companies and Laboratories Combine Efforts to Establish the CardioGenomic Testing Alliance
Coalition aims to raise awareness and utilization of cardiogenomic testing to improve patient outcomes. WASHINGTON, March 22, 2022 /PRNewswire/ — Several leading genomics companies and laboratories, including Illumina, Fulgent Genetics, Invitae, GeneDx, and PerkinElmer Genomics, have formed the CardioGenomic Testing Alliance (CGTA), a collaborative group aimed at raising awareness and utilization of genomic […]
AAN Issues Guidance on Preventing Second Stroke in Those with Plaque in Brain Arteries
MINNEAPOLIS, March 21, 2022 /PRNewswire/ — The use of medications and exercise is more beneficial in preventing a second stroke in people with intracranial atherosclerosis than placing a stent in the blood vessel, according to a new practice advisory issued by the American Academy of Neurology (AAN). The practice advisory is published in the March 21, […]
BioCardia Announces New Center for Medicare and Medicaid Services Reimbursement Code Applicable to the CardiAMP Cell Therapy Procedure
New Procedure Reimbursement Code Expected to Enhance Study Performance for Clinical Centers Participating in the CardiAMP Cell Therapy Heart Failure Trial and the CardiAMP Cell Therapy Chronic Myocardial Ischemia Trial SUNNYVALE, Calif., March 22, 2022 (GLOBE NEWSWIRE) — BioCardia®, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment […]
scPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
Successfully completed all testing; plan to re-submit FUROSCIX® NDA by April 15, 2022 Commercial preparedness activities ramping up to support anticipated Q4 2022 launch of FUROSCIX, if approved Presented key FREEDOM-HF secondary endpoint data at the Cardiovascular Research Foundation Technology and Heart Failure Therapeutics Conference 2022 Ended Q4 with cash, cash […]
CinCor Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Corporate Update
BrigHtn Phase 2 study with CIN-107 for Resistant Hypertension Enrollment Complete with Topline Results Expected in 2H 2022 Topline Data from HALO Phase 2 study with CIN-107 for Uncontrolled Hypertension Expected in 2H 2022 Mason Freeman, M.D. named Chief Medical Officer Conference call and live webcast today at 8:30 AM […]
Valbiotis is Strengthening Its Commitment to CSR by Joining the United Nations Global Compact and Applying the ISO 26000 Standard
LA ROCHELLE, France–(BUSINESS WIRE)–Regulatory News: Valbiotis (Paris:ALVAL) (FR0013254851 – ALVAL, eligible for PEA / SME), a Research and Development company committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases, is strengthening its commitment to Corporate Social Responsibility (CSR) by joining the United Nations Global Compact and applying […]
LeMaitre Joins NASDAQ Dividend Achievers Index – 10 Years of Dividend Increases
BURLINGTON, Mass., March 21, 2022 (GLOBE NEWSWIRE) — LeMaitre (Nasdaq:LMAT), a provider of vascular devices, implants and services, today announced that it has joined the NASDAQ US Broad Dividend Achievers Index. The index is comprised of US securities with at least ten consecutive years of increasing annual regular dividend payments. […]
Recora Announces $20M in Series A Funding and Unveils Cardiac Recovery Program for Health Systems, Medical Groups and Health Plans
NEW YORK, March 21, 2022 (GLOBE NEWSWIRE) — Recora today emerged from stealth to announce $20M in Series A funding while also unveiling Recora’s Cardiac Recovery Program for health systems, medical groups and health plans. The heavily oversubscribed round was led by SignalFire with participation from Valor Equity Partners and existing investor Pear […]
ZOLL Launches Next Generation MCT Solution, Shown to Improve Patient Management Decisions in Largest Ever MCT Trial
The ZOLL Arrhythmia Management System (AMS) mobile cardiac telemetry (MCT) solution adds biometric data to traditional MCT data, helping physicians make more informed treatment plans CHELMSFORD, Mass.–(BUSINESS WIRE)–ZOLL® Medical Corporation, an Asahi Kasei company that manufactures medical devices and related software solutions, today announced the launch of the ZOLL Arrhythmia Management […]



